Advancing a First-in-Class Small Molecule Targeting Creatine-Dependent Thermogenesis
26 Sep 2025
Translational & Clinical Strategy
- This first-in-class small molecule activates the creatine-driven thermogenic pathway, offering a novel mechanism of action distinct from traditional metabolic targets.
- Translational strategy highlights key milestones in preclinical efficacy, safety profiling, and biomarker development to support clinical entry
- The program exemplifies efficient lab-to-clinic progression through integrated discovery, mechanism validation, and early regulatory alignment
Industry Expert
